MacroGenics Reports $32.8 Million Revenue for Q2 2026, Faces $69.6 Million Net Loss

MacroGenics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $32.8 million for the quarter, a substantial increase from $6.9 million in the same period last year. This growth was primarily driven by a $24.5 million regulatory milestone related to its product TZIELD and a notable rise in royalty revenue, which reached $7.3 million compared to $1.3 million in the prior year. For the first half of 2026, total revenues amounted to $39.6 million, up from $13.9 million in the first half of 2025.

Despite the increase in revenue, MacroGenics reported a net loss of $69.6 million from continuing operations for the second quarter, compared to a loss of $42.7 million in the same quarter of 2025. The company’s total costs and expenses decreased to $46.7 million from $50.1 million year-over-year, reflecting a reduction in research and development expenses. The company’s accumulated deficit as of June 30, 2026, stood at $1.3 billion, indicating ongoing financial challenges as it continues to invest heavily in its product development pipeline.

A significant strategic shift occurred with the completion of the sale of its contract development and manufacturing operations (CDMO) to Bora Pharmaceuticals for $119.6 million, finalized on June 30, 2026. This divestiture allows MacroGenics to focus on its core business of developing innovative antibody-based therapeutics. The sale is expected to streamline operations and reduce costs, although it also means the company will rely on third-party manufacturers for its clinical and commercial needs moving forward.

Operationally, MacroGenics is advancing multiple proprietary product candidates, including three clinical-stage antibody-drug conjugates (ADCs) and a bispecific DART molecule. The company has also entered into collaborations with major biopharmaceutical firms, including Gilead Sciences, which could yield additional revenue through milestone payments and royalties. As of June 30, 2026, MacroGenics had cash and cash equivalents of $113.9 million, a significant increase from $57.2 million at the end of 2025, bolstered by the proceeds from the CDMO sale.

Looking ahead, MacroGenics anticipates that its current resources, combined with expected milestone payments and ongoing collaborations, will support its operations through at least 2028. However, the company acknowledges the inherent uncertainties in its financial outlook, particularly regarding the successful development and commercialization of its product candidates, as well as potential market conditions that could impact its operations.